Novartis v. Teva: Mekinist Patent Dispute Dismissed Without Prejudice
Novartis AG filed suit against Teva Pharmaceutical Industries in the Delaware District Court asserting four patents covering its Mekinist (trametinib dimethyl sulfoxide) tablets. The case closed after just 124 days when Novartis voluntarily dismissed all claims without prejudice under Rule 41(a)(1)(A)(i), leaving the door open for potential refiling.
Novartis exits early in Mekinist ANDA battle, keeping claims alive
On July 24, 2025, Novartis AG filed a patent infringement action against Teva Pharmaceutical Industries, Ltd. in the U.S. District Court for the District of Delaware before Judge Gregory B. Williams. The complaint asserted four patents — US9155706B2, US9399021B2, US8580304B2, and US9271941B2 — all directed to Mekinist (trametinib dimethyl sulfoxide) tablets in 0.5 mg and 2 mg dosages, an MEK inhibitor approved for BRAF-mutant melanoma and other cancers.
The case closed on November 25, 2025, just 124 days after filing, when Novartis invoked Rule 41(a)(1)(A)(i) to voluntarily dismiss all claims without prejudice. Because the dismissal was without prejudice, Novartis has not abandoned its enforcement rights — the patent claims could be reasserted in a future action, subject to applicable statutes of limitations and any intervening developments. No merits determination was reached, meaning the validity, enforceability, or infringement of any of the four asserted patents remains unadjudicated.
A resolution in under five months is notably swift for a multi-patent ANDA-type pharmaceutical dispute in Delaware, a jurisdiction known for protracted Hatch-Waxman litigation. The early exit suggests the parties may have reached a confidential licensing or settlement arrangement, though no such agreement appears on the public docket. What drove Novartis to withdraw rather than pursue a 30-month stay or preliminary injunction — and whether Teva’s generic filing will now proceed unchallenged — remains unclear from the public record.
Filing to Voluntary dismissal in 124 days
124 days — resolved significantly faster than the median ANDA patent case in Delaware
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral right to exit
Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order before the defendant serves an answer or a motion for summary judgment. This is the earliest and cleanest form of voluntary dismissal. It requires no judicial approval and takes effect immediately upon filing. Critically, it carries no preclusive effect on the merits — Novartis is not barred from reasserting these claims in a future proceeding.
No merits adjudicationDismissed without prejudice — but the public record is explicit here
The distinction matters significantly: a dismissal with prejudice permanently extinguishes the claims; a dismissal without prejudice does not. Here, the filed notice expressly states ‘without prejudice,’ so there is no ambiguity. Novartis retains the right to refile the same patent claims against Teva’s trametinib ANDA product. Whether it will do so — or whether a private resolution has rendered refiling unnecessary — is not disclosed in the public docket.
Refiling rights preservedTeva avoids a merits ruling — but faces continuing uncertainty
Teva secured no invalidity finding, no non-infringement declaration, and no fee award from this proceeding. While the case is closed, the four Novartis patents remain in force and unadjudicated. Teva’s ANDA pathway for trametinib tablets could face renewed litigation if Novartis refiles or if any 30-month regulatory stay has not yet run. The absence of a final judgment means Teva cannot invoke issue preclusion against these patents in any future dispute.
No preclusive benefit gainedGeneric trametinib market entry remains unresolved
Mekinist is a key oncology asset for Novartis. A voluntary dismissal without prejudice in a pharmaceutical patent case frequently suggests confidential licensing, co-promotion, or authorised generic arrangements — though none is confirmed here. Competitors monitoring the trametinib IP landscape should note that the four asserted patents have not been challenged on the merits and that Novartis retains full enforcement optionality. The commercial pathway for generic trametinib entry remains legally unsettled.
Market entry still uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Multinational pharmaceutical company — holder of US9155706B2 and three further Mekinist patentsSearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer and Hatch-Waxman ANDA applicantSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Heather M. Schneider | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Michael W. Johnson | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Nathan Roger Hoeschen | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Shaw Keller LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i), the most procedurally minimal form of exit available to a plaintiff — filed before any responsive pleading, requiring no court order. The explicit ‘without prejudice’ language is legally significant: it forecloses any argument that Novartis waived or abandoned its claims. No infringement, validity, or claim scope issues were litigated. Both parties leave the proceeding with their legal positions entirely intact, and the four patents remain presumptively valid and unadjudicated.
US9155706B2 and three further patents — Mekinist (trametinib) formulation and use
The four asserted patents — US9155706B2, US9399021B2, US8580304B2, and US9271941B2 — collectively cover Novartis’s Mekinist product, a trametinib dimethyl sulfoxide formulation approved as an MEK inhibitor for treatment of BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma and other malignancies. The patents derive from application numbers filed between 2011 and 2013, placing their priority dates within the period of active clinical and commercial development of trametinib. Together they represent layered protection across formulation, solid-state chemistry, and therapeutic use.
In the oncology small-molecule landscape, multi-patent protection around a single active pharmaceutical ingredient — particularly one as commercially significant as trametinib — is a deliberate litigation strategy. Asserting four patents simultaneously raises the complexity and cost of any invalidity challenge. For competitors, the survival of all four patents without any merit-based adjudication means that the full scope of Novartis’s IP fortress around Mekinist remains intact. Any generic or biosimilar developer targeting this molecule must evaluate each patent independently across formulation, polymorph, and method-of-treatment dimensions.
Should you run an FTO against US9155706B2 and the Mekinist patent family?
Any pharmaceutical company developing a generic, reformulated, or next-generation trametinib product — including ANDA filers, 505(b)(2) applicants, and oncology combination therapy developers — should treat this four-patent cluster as a live enforcement risk. None of these patents has been invalidated or found not infringed. Novartis’s without-prejudice dismissal explicitly preserves its right to refile, meaning the litigation risk has not been resolved — it has merely been paused.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US9155706B2, US9399021B2, US8580304B2, and US9271941B2 against your product’s formulation and process parameters, flag continuation and divisional filings in the same family, and surface prior art landscapes that could support a future IPR or invalidity defence. Run your trametinib FTO analysis before committing to development milestones or regulatory filings.
Run a freedom-to-operate analysis on US9155706B2 to assess your product’s exposure
Run FTO in Eureka →Similar MEK inhibitor and Hatch-Waxman ANDA patent cases in Delaware
Explore patent infringement disputes involving small-molecule oncology formulations and Hatch-Waxman ANDA challenges litigated in the Delaware District Court.
What this case signals for the oncology small-molecule IP landscape
A swift voluntary dismissal across four trametinib patents raises questions about deal-making and generic entry strategy in the MEK inhibitor space.
Without-prejudice dismissals preserve full enforcement leverage
Novartis’s Rule 41(a)(1)(A)(i) exit does not extinguish a single patent claim. In pharma litigation, early voluntary dismissals without prejudice are often associated with confidential licensing or authorised generic deals. Companies monitoring Mekinist competition should treat these four patents as still actively enforceable.
Four unadjudicated patents create a lasting cloud over generic entry
With no invalidity or non-infringement ruling on record, any generic entrant into the trametinib market — not just Teva — faces the full scope of US9155706B2, US9399021B2, US8580304B2, and US9271941B2. Running a thorough FTO analysis against all four patents is essential before committing to development or launch timelines.
Novartis v Teva — key questions answered
Novartis dismissed all claims without prejudice under Rule 41(a)(1)(A)(i), meaning no merits ruling was issued and Novartis retains the right to refile the same patent claims against Teva in a future action. The four patents covering Mekinist (trametinib) remain valid and unadjudicated.
Novartis asserted four patents: US9155706B2, US9399021B2, US8580304B2, and US9271941B2. All four relate to Mekinist (trametinib dimethyl sulfoxide) tablets in 0.5 mg and 2 mg dosages, an MEK inhibitor used in oncology. None was adjudicated on the merits in this proceeding.
The public docket does not disclose a reason. A 124-day voluntary dismissal without prejudice — before any scheduling order or motion practice — is consistent with a confidential licensing, settlement, or authorised generic arrangement, though no such agreement appears on record. The dismissal may also reflect a strategic decision to refile in a different forum or at a different time.
No. A dismissal without prejudice carries no preclusive effect. Teva received no invalidity finding, no non-infringement declaration, and no fee award. All four Novartis patents remain presumptively valid and enforceable. Teva cannot use this dismissal as a defence in any future litigation over the same patents.
The case was filed in the U.S. District Court for the District of Delaware and assigned to Judge Gregory B. Williams under Case No. 1:25-cv-00928. Novartis was represented by McCarter & English LLP; Teva was represented by Shaw Keller LLP.
PatSnap Eureka searches patents and litigation data to answer instantly.